Skip to content
HOME Insights

Fact Sheet: Ncyte® aCardiomyocytes

Explore Ncyte® aCardiomyocytes, human iPSC-derived atrial cardiomyocytes for studying atrial function and assessing drug-induced cardiac responses.
TAKE THE FIRST STEP
Fact Sheet- Ncyte® aCardiomyocytes

Discover Ncyte® aCardiomyocytes

Ncyte® aCardiomyocytes are produced through a well-defined in vitro differentiation process from human induced pluripotent stem cells (iPSC) and express typical atrial cell markers, such as COUP-TFII.

These cells  are the ideal tool to test your drug’s effect on atrial function. They can be applied throughout the entire drug discovery pipeline, from extensive screening for identifying hits to crucial decision-making stages in hit-to-lead and lead optimization processes.
Topics
ABOUT US
Predict future safety and efficacy more efficiently
For more than a decade, Ncardia has been pioneering innovations in human induced pluripotent stem cells (iPSC). Our iPSC drug discovery platforms have been successfully leveraged by large biopharmas, up-and-coming drug discovery firms and multinational research consortia to advance therapeutic candidates for cardiovascular, neurological and other disease areas.

Download the fact sheet by filling out the form below: